Edition:
United States

Suda Ltd (SUD.AX)

SUD.AX on Australia Stock Exchange

0.02AUD
25 Sep 2017
Change (% chg)

$0.00 (+4.76%)
Prev Close
$0.02
Open
$0.02
Day's High
$0.02
Day's Low
$0.02
Volume
462,912
Avg. Vol
1,713,772
52-wk High
$0.03
52-wk Low
$0.01

Latest Key Developments (Source: Significant Developments)

Suda posts FY net loss for period attributable to members of $1.2 mln
Wednesday, 30 Aug 2017 11:10pm EDT 

Aug 31 (Reuters) - Suda Ltd :FY revenues from ordinary activities up 23.0 percent to $7.2 million.FY net loss for period attributable to members $1.2 million versus loss of $2.3 million.  Full Article

Suda Ltd enters licensing agreement for Zolpimist in China
Tuesday, 8 Nov 2016 04:40pm EST 

Suda Ltd : Suda enters licensing agreement for Zolpimist in china . Suda receives an upfront cash payment of us$300,000 . Co and Eddingpharm (Asia) Macao Commercial Offshore Limited (Eddingpharm), announce that companies have entered into an exclusive license agreement . Is entitled to receive a further milestone payment of us$200,000 following registration of product in china . Agreement for development and commercialisation of Suda's novel zolpimist™ oral spray of zolpidem tartrate to treat insomnia in china .Total value of deal could exceed us$26 million based on eddingpharm's forecast sales for first 15 years.  Full Article

Suda Ltd receives a statement of claim regarding lawsuit between co and HC Berlin Pharma AG
Friday, 3 Jun 2016 12:53am EDT 

Suda Ltd : Co has received a statement of claim in relation to a lawsuit between the company and hc Berlin pharma ag (in liquidation) . Statement of claim contains assertions that are not based on fact therefore directors believe that claim is without significant merit and will be vigorously defended .  Full Article

Suda amends agreement with Amherst pharmaceuticals
Wednesday, 9 Dec 2015 07:34pm EST 

Suda Ltd:Suda amends agreement with Amherst pharmaceuticals.Suda has expanded its territorial rights to zolpimist® to include South America, Central America and South Africa.Amended its agreement with Amherst pharmaceuticals in relation to zolpimist® for insomnia and sud-002 for nausea and vomiting.Says Suda will pay Amherst a 6 to 12 per cent share of income from suda's commercialisation of zolpimist® in the original territories.  Full Article

Suda allowed first U.S. patent for SUD-003 and SUD-004
Wednesday, 7 Oct 2015 07:06pm EDT 

Suda:Says co has been allowed its first patent in the USA for "Oral Spray Formulations and Methods for Administration of Sildenafil" for the treatment of SSRI-induced erectile dysfunction and pulmonary arterial hypertension.  Full Article

BRIEF-Suda posts FY net loss for period attributable to members of $1.2 mln

* FY revenues from ordinary activities up 23.0 percent to $7.2 million